BERGISCH GLADBACH, Germany--27 Jun--PRNewswire/ InfoQuest
Miltenyi Biotec, the world's leading cell innovation company, announced today that it opened a new office in Seoul, Korea, enlarging the company's Asia-Pacific presence to six locations in five countries.
"Miltenyi Biotec recognizes the potential of a Korean presence in achieving strong, steady growth and expanding our global reach with a team of talented people," said CEO Boris Stoffel. "Our new team has an exceptional ability to partner with scientists and clinicians to generate exciting opportunities."
Daesuk Oh has been appointed General Manager of the new office in the Gangnam district of Seoul. "Our location will be instrumental in developing deeper relationships with a host of stem cell, immunology, translational research, and clinical customers, as well as prospective research and clinical institutions throughout South Korea. We're excited for the opportunity to bring Miltenyi Biotec's solutions to scientists and clinicians who can truly benefit from the quality and reliability the portfolio is known for," said Oh.
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance biomedical research. From research tools to GMP reagents, Miltenyi is making the promise of cell therapy a reality. The company's integrated portfolio of tools supports the translation of basic research into practical applications for human health. Scientists and clinicians around the world use Miltenyi-enabling technologies for effective sample preparation, cell isolation, flow cytometry, cell culture, molecular analysis and preclinical imaging. The MACS(R) brand has set standards in the industry and is trusted across basic, translational, and clinical research settings. The company also offers comprehensive technical support and training through its MACS(R) Academy. Miltenyi Biotec has 1,400 employees in 22 countries.
Media Contact:
Prof. Dr. Uwe Heinlein
Phone: +49-2204-8306-6590
E-mail: [email protected]
http://www.miltenyibiotec.com
Source: Miltenyi Biotec GmbH
Company targets total revenue growth rate of 25-30% in 2025. Dusit Thani Public Company Limited (DUSIT) has officially entered the final stage of its nine-year strategic roadmap (2016-2025), now progressing through Phase 3: "Unlock Value," which is focused on capitalising on the business expansion and investments made since 2016. Given the current economic conditions, geopolitical tensions, and the tourism landscape in Thailand, the company has revised its overall growth outlook in 2025. The
Gulftex marks 25th anniversary with bold sustainability vision and global safety innovation
—
Gulftex Co., Ltd., a leading Thai manufacturer of personal p...
KuCoin Thailand Now Open to All! Platform Welcomes Public Access with New Mascot and Reward Campaign
—
KuCoin Thailand marks an exciting new chapter as it...
ULTIMATE GAME COMMITS OVER 100 MILLION BAHT TO ADVANCE THAI GAMING INDUSTRY AND EXPAND ACROSS SOUTHEAST ASIA
—
Ultimate Game Co., Ltd., a premier Thai-bas...
"Nuovo Plus Powers Thailand's Green Future with 'Nuovo Plus 2025: Powering the Future with BESS'
—
Nuovo Plus Co., Ltd., a leading energy management syste...
WINMED จับมือพันธมิตร Miltenyi Biotec ประเทศเยอรมัน จัดเสวนาออนไลน์ หัวข้อ "Cancer Immunotherapy: The Past, The Present, and The Possibility"
—
WINMED จับม...